<DOC>
	<DOCNO>NCT01449019</DOCNO>
	<brief_summary>The purpose study determine contribution endogenous Glucagon-like peptide 1 ( GLP-1 ) postprandial secretion insulin glucagon incretin effect healthy subject patient type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>The Role Endogenous Glucagon-like Peptide 1 ( GLP-1 ) Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>male female ( postmenopausal , surgically sterile use doublebarrier method contraception ) healthy subject patient type 2 diabetes mellitus ( T2DM ) must able complete 1 week washout current antidiabetic medication Age 3070 year HbA1c ( Hemoglobin A1c ) ≤11 % screen Body mass index ( BMI ) &lt; 40 kg/m2 Patients type 2 diabetes mellitus ( T2DM ) : Must fast blood glucose ≤12.2 mmol/L ( 240 mg/dL ) screen Able provide write informed consent prior study participation Able communicate well investigator comply requirement study Patients type 1 diabetes mellitus ( T1DM ) , diabetes result pancreatic injury , secondary form diabetes ( eg Cushing , acromegaly ) Need insulin within previous 3 month Use Thiazolidinediones previous 4 week Significant concomitant disease complication diabetes ( i.e . nephropathy , autonomic dysfunction , orthostasis ) . Treatment systemic steroid thyroid hormone ( unstable dosage ) . Patients history gastrointestinal surgery , e.g . partial bowel resection , partial gastric resection , etc . Participation clinical investigation within 4 week prior dose longer required local regulation . Donation loss 400 mL blood within 8 week prior dose . Significant illness within two week prior dose . Past medical history clinically significant ECG abnormality family history prolong QTinterval syndrome . History clinically significant drug allergy ; history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity study drug drug similar study drug . history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection ; history clinical evidence pancreatic injury pancreatitis ; history presence impair renal function indicate abnormal creatinine urea value abnormal urinary constituent ( e.g. , albuminuria ) ; evidence urinary obstruction difficulty void screen ; Polymorphonuclears &lt; 1500/µL inclusion platelet count &lt; 100,000/μL screen baseline . History immunocompromise . Evidence liver disease indicate abnormal transaminase alkaline phosphatase exceed twice upper limit normal range , serum bilirubin exceed value 27 µmol/L ( 1.6 mg/dL ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>Exendin ( 9-39 )</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glucagon</keyword>
	<keyword>T2DM</keyword>
	<keyword>incretin effect</keyword>
	<keyword>human physiology</keyword>
</DOC>